This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Acute Migraine

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

Sponsored by Pfizer

About this trial

Last updated 2 years ago

Study ID

BHV3500-202

Status

Completed

Type

Interventional

Phase

Phase 2/Phase 3

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 4 years ago

What is this trial about?

The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. * BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.

What are the participation requirements?

Yes

Inclusion Criteria

- 2-8 moderate to severe migraines/month within the last 3 months

- Migraine attacks present for more than 1 year with age of onset of migraines prior to 50 years of age

- Migraine attacks, on average, lasting about 4-72 hours if untreated

- Less than 15 days with headaches (migraine or non-migraine) per month in each of the 3 months prior to the screening visit

- Ability to distinguish migraine attacks from tension/cluster headaches

- Participants with contraindications for use of triptans may be included provided they meet all other study entry criteria

No

Exclusion Criteria

- History of human immunodeficiency virus disease

- History of basilar or hemiplegic migraine

- Current diagnosis of major depressive disorder requiring treatment with atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder

- History of nasal surgery in the 6 months preceding the screening visit

- History of gallstones or cholecystectomy

- History of gastric, or small intestinal surgery (including gastric bypass, gastric banding, gastric sleeve, gastric balloon, etcetera), or other disease or condition (for example, chronic pancreatitis, ulcerative colitis, etcetera) that causes malabsorption.

- Body mass index ≥ 33

- Hemoglobin A1c ≥6.5%

Locations

Location

Status